Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Mirabegron 50 mg Prolonged-release Tablet Formulations in Healthy Thai Subjects Under Fasting Conditions
TCTR20230713003Phase 1Unknown
- Sponsor
- Novartis
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of mirabegron (2 arms), sponsored by Novartis. Primary endpoint: Primary pharmacokinetic bioequivalence. Status: unknown.
02
Drugs
mirabegron
Beyond the preview
Go deeper on TCTR20230713003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230713003.